Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“As of January 2021 the FDA had reviewed only 0.6 percent of the applications.”
UnverifiableConfidence: LOW

Reasoning

The evidence excerpt from Reason.com explicitly mentions the 0.6 percent figure for FDA review progress as of January 2021, matching the claim word for word. No contradictory information is presented.

On confidence: The claim is directly supported by the provided source, which states that as of January 2021 the FDA had managed to look at just 0.6 percent of the applications.

Important context

The source is a secondary report summarizing court filings and FDA statements about the volume of nicotine product applications and the agency's capacity to review them.

Evidence

Supporting (1)

Limitations

The evidence is a secondary reporting article; primary FDA data or official statements are not directly cited, so verification relies on the accuracy of the reporting source. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:41 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum